GLP-1 Weight Loss: Clinical Evidence & Biomarker Insights

Last reviewed: June 2, 2026

Last updated: June 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, GLP-1 receptor agonists have demonstrated substantial weight loss benefits in multiple randomized controlled trials, with participants losing 15-22% of baseline body weight over 68 weeks. However, individual response varies significantly, and understanding your metabolic predispositions can help contextualize realistic outcomes for your situation.

Weight loss with GLP-1 involves complex mechanisms—appetite suppression, slowed gastric emptying, and metabolic signaling across the brain and gut. PlexusDx supports precision wellness by helping you understand your unique genetic predispositions in GLP-1 and related metabolic pathways, enabling more targeted conversations with your healthcare provider.

How GLP-1 Medications Work at the Cellular Level

GLP-1 (glucagon-like peptide-1) is an incretin hormone naturally released after eating. GLP-1 receptor agonists mimic this hormone, binding to receptors throughout the brain, gut, and pancreas. This activation reduces appetite signals in the hypothalamus, slows stomach emptying, and increases insulin secretion—creating multiple pathways toward weight reduction.

The medication's effect on appetite centers is particularly powerful. Patients report reduced hunger, earlier fullness, and diminished food cravings. These neurobiological changes, combined with improved blood sugar control, create conditions for sustained caloric deficit without the extreme hunger typical of diet-only approaches.

Clinical Trial Evidence: What the Data Actually Shows

Major trials (STEP, SELECT, SUSTAIN) demonstrated dose-dependent weight loss averaging 15-22% over 68 weeks for semaglutide and similar outcomes for tirzepatide. Cardiovascular benefits also emerged, including reduced major adverse cardiac events in the SELECT trial (Ozempic/Wegovy). Response was not uniform—some participants lost 30%+ body weight while others achieved 5-10% losses.

Trial/Medication	Study Duration	Average Weight Loss	Key Outcome
STEP (Semaglutide)	68 weeks	15-17% body weight	Sustained weight reduction; improved cardiometabolic markers
SUSTAIN 6 (Semaglutide)	104 weeks	14% body weight	Reduced cardiovascular events in type 2 diabetes
SELECT (Semaglutide)	104 weeks	17.4% body weight	Reduced major adverse cardiac events in non-diabetic adults
SURMOUNT (Tirzepatide)	68 weeks	20-22% body weight	Greater weight loss vs semaglutide; improved metabolic parameters

Individual Response Variation: Why Your Results May Differ

Clinical averages mask significant individual variability. Genetic variations in GLP1R (the GLP-1 receptor gene), GIPR (glucose-dependent insulinotropic polypeptide receptor), and metabolic genes like FTO and MC4R influence how effectively your body responds to these medications. Two patients on identical doses may experience markedly different satiety, side effects, and weight loss trajectories.

Factors beyond genetics also shape outcomes: baseline metabolic health, medication adherence, dietary patterns, physical activity, sleep quality, and stress levels all modify treatment response. Understanding both your genetic predispositions and modifiable lifestyle factors helps create realistic expectations and informs dose adjustments with your provider.

Safety Considerations and Who Should Consult a Provider First

GLP-1 medications are generally well-tolerated but carry specific contraindications and risks. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) are absolute contraindications. Diabetic retinopathy, severe pancreatitis history, and certain gallbladder conditions require careful provider evaluation. Pregnancy is not supported, and thyroid monitoring may be warranted for some patients.

Common side effects—nausea, vomiting, constipation, decreased appetite—typically resolve within weeks but can impact adherence. Rare serious adverse events include acute pancreatitis and acute kidney injury, though causation remains debated. A qualified healthcare provider must conduct full medical history review, medication screening, and baseline labs before initiation. This is not a treatment for everyone, and individualized medical judgment is essential.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals your predispositions across key GLP-1 and metabolic pathways, including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. These variants may help provide context about your baseline metabolic profile and theoretical receptor sensitivity, supporting a more informed conversation with your provider about treatment potential.

The genetic test does not predict your exact medication response or guarantee outcomes. Rather, it identifies predispositions in peptide signaling pathways that influence appetite regulation and energy metabolism. When interpreted with clinical context—your medical history, current medications, and lifestyle—these insights can inform whether a GLP-1 approach aligns with your biology and should be explored further.

Understanding your genetic predispositions may help you and your provider set realistic expectations, select between formulations (injection vs. oral), and optimize dosing or adjunctive strategies. This personalized context transforms a generic clinical trial average into a starting point tailored to your individual presentation, supporting more confident shared decision-making.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.